+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease (Influenza, MMR, Pneumonia, Meningitis, Hepatitis, Tap, Hib, Polio, etc) & Companies

  • ID: 4587690
  • Report
  • July 2018
  • Region: Global
  • 232 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now
The Pediatric Vaccine Market is Projected to Exceed US$ 48 Billion by 2024

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • MORE

Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024. Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.

Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention. According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.

This report titled “Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Pediatric (Infants) Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at Noteworthy Rate in the Forthcoming Years

The report studies the market of the following vaccine: Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine. Pneumococcal and Combination Vaccines together hold the significant market share in pediatric (infants) vaccine market and is expected to continue so during the forecast period.

Nearly 650 Million Vaccines Doses will be administered in Pediatrics (Infants) by the year 2024

As per our analysis; it is estimated that by the year 2024, the doses of vaccines administered will reach nearly 650 Million. The number of vaccine doses is expected to grow considerably during the forecast period due to growing awareness among the parents about the benefits of vaccines and also the developing countries around the world that now have included a number of vaccines to their national immunization programme as per WHO recommendations, which indeed will drive the pediatric vaccine market in recent years.

Regional - Immunization Profile

The report also comprises of the en-detail study of global and regional immunization profile: By Diseases such as Measles, Mumps, Rubella, Diphtheria, Tetanus, Polio and so on and By Regions such as Africa (AFR), Americas (AMR), Eastern Mediterranean (EMR), Europe (EUR), South-East Asia (SEAR), Western Pacific (WPR) and Global.

Company Analysis:

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently with vaccine business globally. These companies have been studied thoroughly in the report.

Global Pediatric (Infants) Vaccine Market has been extensively studied from 3 major points:

1. Pediatrics Vaccines (Disease wise) Market & Forecast
2. Number of Vaccinated Pediatric (Infants) (Disease wise) & Forecast
3. Doses of Vaccines Administered in Pediatric (Infants) (Disease wise) & Forecast

This market research report provides a complete analysis of the Global Pediatric (Infants) Vaccine Market and their projections for the upcoming years, Growth Drivers, Challenges, and Disease wise number of reported cases.

By Disease:

  • Influenza
  • MMR (Measles, Mumps, and Rubella)
  • Pneumonia
  • Meningitis
  • Hepatitis
  • Tap (Diphtheria, Tetanus, Pertussis)
  • Haemophilus influenzae type B
  • Polio
  • Rotavirus
  • Varicella
  • Combination Vaccine

Key Companies Covered in the Report:

  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Pfizer
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • MORE

1. Research Findings

2. Pediatric (Infant) Vaccines Market (2011 - 2024)

3. Market & Numbers Share - Pediatric Vaccines
3.1 Pediatric Vaccine Market Share
3.2 Pediatric Vaccinated Population Share
3.3 Pediatric Doses of Vaccines Administered Share
3.4 Vaccine Companies Market Share

4. Pediatric Vaccinated Numbers

5. Pediatric Doses of Vaccines Administered

6. Disease wise - Pediatric (Infants) Vaccines Market (2011 - 2024)
6.1 Influenza
6.2 MMR (Measles, Mumps, and Rubella Vaccine)
6.3 Pneumococcal
6.4 Meningococcal
6.5 Hepatitis
6.6 DTaP
6.7 Haemophilus Influenzae Type B (HIB)
6.8 Combos (Combination)
6.9 Polio
6.10 Rotavirus
6.11 Varicella

7. Disease wise - Numbers of Vaccinated Pediatric (Infants) (2011 - 2024)
7.1 Influenza
7.2 MMR
7.3 Pneumococcal
7.4 Meningococcal
7.5 Hepatitis
7.6 DTaP
7.7 Hib (Haemophilus Influenzae Type B)
7.8 Combos (Combination Vaccines)
7.9 Polio
7.10 Rotavirus
7.11 Varicella

8. Disease wise - Doses of Vaccines Administered in Pediatric (Infants) (2011 - 2024)
8.1 Influenza
8.2 MMR
8.3 Pneumococcal
8.4 Meningococcal
8.5 Hepatitis
8.6 DTaP
8.7 Hib (Haemophilus Influenzae Type B)
8.8 Polio
8.9 Rotavirus
8.10 Varicella

9. Disease wise - Immunization Profile
9.1 Immunization Coverage (%) in Infants
9.2 Global Immunization Profile
9.3 Regional Immunization Profile
9.3.1 Measles - Number of Reported Cases
9.3.2 Mumps - Number of Reported Cases
9.3.3 Rubella - Number of Reported Cases
9.3.4 Rubella (CRS) - Number of Reported Cases
9.3.5 Diphtheria - Number of Reported Cases
9.3.6 Tetanus (Neonatal) - Number of Reported Cases
9.3.7 Tetanus (Total) - Number of Reported Cases
9.3.8 Pertussis - Number of Reported Cases
9.3.9 Polio - Number of Reported Cases
9.3.10 Yellow Fever - Number of Reported Cases
9.3.11 Japanese encephalitis - Number of Reported Cases

10. Vaccines Key Players Sales (2011 - 2024)
10.1 GlaxoSmithKline, plc.’s Vaccines Sales
10.2 Merck & Co. Vaccines Sales
10.3 Sanofi Pasteur’s Vaccines Sales
10.4 Pfizer, Inc.’s Vaccines Sales
10.5 Global - Other Companies Vaccines Sales

11. Vaccines - Products and Pipeline
11.1 GSK Vaccine Product Pipeline
11.2 Merck Vaccine Product Pipeline
11.3 Sanofi Vaccine Product Pipeline
11.4 Pfizer Vaccine Product Pipeline

12. Top Mergers and Acquisitions in the Vaccine Industry

13. Vaccines and Regulator’s Interventions
13.1 Making and Meeting Standards of Quality and Safety
13.2 Vaccine Funding

14. Vaccine Market Drivers
14.1 Inclusion in National Immunization Schedule
14.2 Growing Immunization Coverage for HPV Vaccines
14.3 Increase in Prevalence of Infectious Diseases
14.4 Global Immunization Vision and Strategy (GIVS)
14.5 GAVI Model Fuelling Vaccine Manufacturers
14.5.1 The Partnership Model
14.5.2 The Business Model
14.6 Increasing Vaccine Availability in United States
14.7 The Vaccine Safety Data link Project
14.8 The Vaccine Injury Compensation Program
14.9 Transforming of Vaccine Technologies
14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
14.11 Continuous Focus on Effective Communication Strategies

15. Vaccines Market Challenges
15.1 Hurdles to Optimal use of Licensed Vaccines
15.1.1 Technical Obstacles
15.1.2 Economic Obstacles
15.1.3 Cultural Obstacles
15.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
15.2.1 Legal Obstacles
15.2.2 General Technical Barriers
15.2.3 Economic Barriers
15.2.4 Regulatory Barriers
15.3 Shortening the Timeline for Vaccine Development
15.4 Refusal/Resistance to Vaccination
15.4.1 Vaccine Adverse Event Reporting System
15.5 Vaccine Shortages and Delays
15.6 Obstacles in Vaccine Research & Development
15.7 Barriers to New Entrants in the Vaccines Market

List of Figures
Figure 2-1: Global - Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2017
Figure 2-2: Global - Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 - 2024
Figure 3-1: Global - Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2017
Figure 3-2: Global - Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2018 - 2024
Figure 3-3: Global - Vaccinated Infant (Pediatric) Share (Percent), 2011 - 2017
Figure 3-4: Global - Forecast for Vaccinated Infant (Pediatric) Share (Percent), 2018 - 2024
Figure 3-5: Global - Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2017
Figure 3-6: Global - Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2018 - 2024
Figure 3-7: Global - Key Players Vaccines Market Share (Percent), 2011 - 2017
Figure 3-8: Global - Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
Figure 4-1: Global - Number of Vaccinated Infant (Pediatric) (Million), 2011 - 2017
Figure 4-2: Global - Forecast for Number of Vaccinated Infant (Pediatric) (Million), 2018 - 2024
Figure 5-1: Global - Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2017
Figure 5-2: Global - Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2018 - 2024
Figure 6-1: Influenza - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 6-2: Influenza - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 6-3: MMR - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 6-4: MMR - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 6-5: Pneumococcal - Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2017
Figure 6-6: Pneumococcal - Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 - 2024
Figure 6-7: Areas with frequent epidemics of meningococcal meningitis
Figure 6-8: Meningococcal - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 6-9: Meningococcal - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 6-10: Hepatitis - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 6-11: Hepatitis - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 6-12: DTaP - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 6-13: DTaP - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 6-14: Haemophilus Influenzae Type B (HIB) - Vaccines Market (Million US$), 2011 - 2017
Figure 6-15: Haemophilus Influenzae Type B (HIB) - Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 6-16: Combos (Combination) - Vaccines Market (Billion US$), 2011 - 2017
Figure 6-17: Combos (Combination) - Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-18: Polio - Vaccines Market (Million US$), 2011 - 2017
Figure 6-19: Polio - Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 6-20: Rotavirus Deaths Under Five Years of Age per 100 000 Population <5 Years of Age, 2013
Figure 6-21: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
Figure 6-22: Rotavirus - Vaccines Market (Million US$), 2011 - 2017
Figure 6-23: Rotavirus - Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 6-24: Varicella - Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 6-25: Varicella - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 7-1: Influenza - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-2: Influenza - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-3: MMR - Number of Vaccinated Infants (Pediatric) (Million), 2011 - 2017
Figure 7-4: MMR - Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2018 - 2024
Figure 7-5: Pneumococcal - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-6: Pneumococcal - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-7: Meningococcal - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-8: Meningococcal - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-9: Hepatitis - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-10: Hepatitis - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-11: DTaP - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-12: DTaP - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-13: Hib (Haemophilus Influenzae Type B) - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-14: Hib (Haemophilus Influenzae Type B) - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-15: Combos (Combination Vaccines) - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-16: Combos (Combination Vaccines) - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-17: Polio - Number of Infants Immunized (Million), 2011 - 2017
Figure 7-18: Polio - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 7-19: Rotavirus - Number of Infants Immunized (Million), 2011 - 2017
Figure 7-20: Rotavirus - Forecast for Number of Infants Immunized (Million), 2018 - 2024
Figure 7-21: Varicella - Number of Vaccinated Infants (Million), 2011 - 2017
Figure 7-22: Varicella - Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 8-1: Influenza - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-2: Influenza - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-3: MMR - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-4: MMR - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-5: Pneumococcal - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-6: Pneumococcal - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-7: Meningococcal - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-8: Meningococcal - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-9: Hepatitis - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-10: Hepatitis - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-11: DTaP - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-12: DTaP - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-13: Hib (Haemophilus Influenzae Type B) - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-14: Hib (Haemophilus Influenzae Type B) - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-15: Polio - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-16: Polio - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-17: Rotavirus - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-18: Rotavirus - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 8-19: Varicella - Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 8-20: Varicella - Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 10-1: Global - GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-2: Global - Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-3: Global - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-4: Global - Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-5: Global - Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-6: Global - Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-7: Global - Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-8: Global - Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-9: Global - Other Companies Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-10: Global - Forecast for Other Companies Vaccines Sales (Billion US$), 2018 - 2024
Figure 11-1: GSK Vaccine Product Pipeline
Figure 14-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 14-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 14-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-5: US Retail Clinics Expected to Surge by 2017

Lists of Tables
Table 9-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Table 9-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
Table 9-3: Vaccines - Number of Reported Cases, 2011 - 2017
Table 9-4: Measles - Number of Reported Cases, 2001 - 2016
Table 9-5: Mumps - Number of Reported Cases, 2001 - 2016
Table 9-6: Rubella - Number of Reported Cases, 2001 - 2016
Table 9-7: Rubella (CRS) - Number of Reported Cases, 2001 - 2016
Table 9-8: Diphtheria - Number of Reported Cases, 2001 - 2016
Table 9-9: Tetanus (Neonatal) - Number of Reported Cases, 2001 - 2016
Table 9-10: Tetanus (Total) - Number of Reported Cases, 2001 - 2016
Table 9-11: Pertussis - Number of Reported Cases, 2001 - 2016
Table 9-12: Polio - Number of Reported Cases, 2001 - 2016
Table 9-13: Yellow Fever - Number of Reported Cases, 2001 - 2016
Table 9-14: Japanese Encephalitis - Number of Reported Cases Reported, 2006 - 2016
Table 11-1: Merck Vaccine Product Pipeline
Table 11-2: Sanofi Vaccine Product Pipeline
Table 11-3: Pfizer Vaccine Product Pipeline
Table 12-1: Vaccine Mergers & Acquisitions
Table 14-1: United States Immunization Schedule
Table 14-2: Afghanistan Immunization Schedule
Table 14-3: Norway Immunization Schedule
Table 14-4: India Immunization Schedule
Table 14-5: Vietnam Immunization Schedule
Table 14-6: Worldwide - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 14-7: Goal-Level Indicators, 2015 & 2020
Table 14-8: Improvement Strategies or Requirements - the Joint Commission and the Project’s Collaborating Organizations

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll